These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17075187)

  • 1. [Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Oct; 29(5):289-94. PubMed ID: 17075187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of IL-6 and Development of Anti-IL-6R Antibody.
    Kishimoto T
    Keio J Med; 2019; 68(4):96. PubMed ID: 31875623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
    Ohsugi Y; Tsuchimoto N
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
    [No Abstract]   [Full Text] [Related]  

  • 5. [IL-6 targetting therapy for inflammatory immune diseases].
    Nishimoto N
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1795-800. PubMed ID: 17037317
    [No Abstract]   [Full Text] [Related]  

  • 6. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
    Nishimoto N
    Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab.
    Venkiteshwaran A
    MAbs; 2009; 1(5):432-8. PubMed ID: 20065633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
    Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
    Nishimoto N
    Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The blockade of IL-6 signaling in rational drug design.
    Adachi Y; Yoshio-Hoshino N; Nishimoto N
    Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
    Nakahara H; Nishimoto N
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
    Nishimoto N; Kishimoto T; Yoshizaki K
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i21-7. PubMed ID: 11053081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical benefits of anti-human IL-6 receptor antibody therapy].
    Nishimoto N
    Clin Calcium; 2007 Apr; 17(4):562-8. PubMed ID: 17404486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
    Ding C; Jones G
    Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting interleukin-6 in rheumatoid arthritis.
    Choy E
    Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atlizumab: anti-IL-6 receptor antibody-Chugai, anti-interleukin-6 receptor antibody-Chugai, MRA-Chugai.
    BioDrugs; 2003; 17(5):369-72. PubMed ID: 14498766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
    Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
    Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.